Atai Beckley Q3 2025 Earnings Report

Atai Beckley EPS Results

• Actual EPS: -$0.28
• Consensus EPS: -$0.12
• Beat/Miss: Missed by -$0.16
• One Year Ago EPS: N/A

Atai Beckley Revenue Results

• Actual Revenue: $0.74 million
• Expected Revenue: $0.05 million
• Beat/Miss: Beat by +$690.00 thousand
• YoY Revenue Growth: N/A

Atai Beckley Announcement Details

• Quarter: Q3 2025
• Date: 11/12/2025
• Time: Before Market Opens
• Conference Call Date: Wednesday, November 12, 2025
• Conference Call Time: 7:00AM ET

Atai Beckley (NASDAQ:ATAI) is a clinical-stage biotechnology company developing novel therapies for mental health disorders through a decentralized model of wholly owned subsidiaries and strategic collaborations. Founded in 2018 by entrepreneur Christian Angermayer, Atai Beckley focuses on addressing unmet needs in conditions such as treatment-resistant depression, post-traumatic stress disorder (PTSD), substance use disorders and attention-deficit/hyperactivity disorder (ADHD). The company’s approach combines psychedelic and non-psychedelic molecules alongside digital therapeutics to create differentiated treatment paradigms.

The Atai Beckley pipeline features multiple proprietary programs, including a deuterated psilocybin analog designed for enhanced stability and tolerability, an intravenous synthetic DMT administered via a patented delivery system, and novel ketamine derivatives engineered to minimize dissociative side effects. In addition, Atai Beckley has launched subsidiaries such as Perception Neuroscience, which focuses on nasal DMT delivery, and DemeRx, which develops treatments for addiction. These platform technologies are supplemented by biomarker development and patient-reported outcome tools aimed at optimizing clinical trial design and therapeutic impact.

Headquartered in Berlin, Germany, with research and development operations in North America and Europe, Atai Beckley conducts global clinical trials across multiple geographies. The company entered the public markets in 2021 through a special purpose acquisition company (SPAC) merger, providing capital to advance lead programs into late-stage studies. Atai Beckley leverages partnerships with academic institutions, contract research organizations and regulatory experts to streamline development pathways and support potential approvals in major markets.

Governed by founder Christian Angermayer and a leadership team drawn from established biopharma and academic backgrounds, Atai Beckley emphasizes robust clinical evidence and regulatory compliance. The company’s scientific advisory board includes experts in psychiatry, neurology and drug delivery, reinforcing its commitment to pioneering safe, effective treatments that could transform the standard of care for patients with chronic mental health conditions.